RESUMO
GH has multiple effects on growth and metabolism, and these functions are mediated through binding to specific cell surface receptors. The human GH receptor (GHR) exists in two known isoforms; in one form exon 3 is present (GHR3+), and in the other, exon 3 is absent (GHR3-). Recent reports have suggested that the expression of the two isoforms is tissue specific and/or developmentally regulated. We used a reverse transcription-polymerase chain reaction assay to study the expression pattern of the two isoforms in a variety of tissues from normal subjects and patients with acromegaly. In skeletal muscle from both normal subjects and patients with acromegaly, the GHR3+ transcript was expressed, either alone or together with the shorter (GHR3-) transcript. When multiple tissues from six subjects were tested, the expression of the two isoforms varied among subjects, whereas different tissues from the same subject showed the same expression pattern. These results indicate that the expression of the GHR isoforms is not tissue specific. Instead, the expression of the GHR isoforms appears to be specific for each individual, suggesting that it is under the control of factors that affect all tissues in the body.
Assuntos
Éxons , Regulação da Expressão Gênica , Receptores da Somatotropina/biossíntese , Receptores da Somatotropina/genética , Tecido Adiposo/metabolismo , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Sequência de Bases , Osso e Ossos/metabolismo , Cartilagem/metabolismo , Criança , Pré-Escolar , Primers do DNA , Feminino , Humanos , Lactente , Fígado/metabolismo , Masculino , Pessoa de Meia-Idade , Dados de Sequência Molecular , Músculo Esquelético/metabolismo , Especificidade de Órgãos , Reação em Cadeia da Polimerase , Pele/metabolismoRESUMO
A double-blind, placebo-controlled, cross-over study was carried out in 25 healthy, nonobese middle-aged men to test the effect of guar gum on glucose and lipid metabolism, blood pressure, and fibrinolysis. Ten grams guar or placebo granulate was given three times a day for 6 wk with a 2-wk run-in before and a wash-out period after. Decreases in fasting blood glucose (P < 0.001), cholesterol (P < 0.001), triglycerides (P < 0.05), plasminogen activator inhibitor-1 activity (P < 0.01), systolic blood pressure (P < 0.01), and diastolic blood pressure (P < 0.001) were seen during guar treatment when compared with placebo. Insulin sensitivity, measured with the euglycemic-clamp technique, increased (P < 0.01), adipose tissue-glucose uptake measured in vitro increased (P < 0.001), and 24-h urinary excretion of sodium and potassium increased (P < 0.001) during guar treatment. Fasting plasma insulin, renin, aldosterone, and fibrinogen concentrations as well as skeletal-muscle electrolytes, urinary catecholamines, and body weight remained unaltered. These findings support a role for guar in the treatment of the metabolic syndrome in which insulin resistance seems to play a pivotal role.
Assuntos
Glicemia/metabolismo , Pressão Sanguínea/efeitos dos fármacos , Fibrinólise/efeitos dos fármacos , Galactanos/farmacologia , Insulina/farmacologia , Lipídeos/sangue , Mananas/farmacologia , Tecido Adiposo/efeitos dos fármacos , Tecido Adiposo/metabolismo , Doenças Cardiovasculares/prevenção & controle , Colesterol/sangue , Método Duplo-Cego , Galactanos/administração & dosagem , Galactanos/uso terapêutico , Glucose/metabolismo , Humanos , Masculino , Mananas/administração & dosagem , Mananas/uso terapêutico , Pessoa de Meia-Idade , Placebos , Gomas Vegetais , Inibidor 1 de Ativador de Plasminogênio/metabolismo , Potássio/urina , Sódio/urina , Triglicerídeos/sangueRESUMO
Several previous studies have suggested that hypertension is associated with altered sodium transport across the cell membrane. The aim of the present study was to study the skeletal muscle Na:K ratio in relation to blood pressure and glucose tolerance in obese and non-obese men. Muscle biopsies were taken from the femoral vastus lateralis muscle in men aged 52 +/- 5 years and the electrolytes were analyzed. Ten obese men with impaired glucose tolerance and hypertension, 10 obese normotensive controls, 10 lean men with hypertension and 10 lean normotensive controls participated in the study. Higher insulin levels were found in both hypertensive groups compared with the respective normotensive groups. Increased muscle Na:K ratio was found in obesity (P less than 0.01) and this was further enhanced when combined with hypertension and impaired glucose tolerance (P less than 0.001). However, hypertension in lean individuals was not associated with an increased muscle Na:K ratio. These data suggest that the increased muscle Na:K ratio in obese subjects and those with impaired glucose tolerance is not solely due to insulin resistance and hyperinsulinemia. Furthermore, the data clearly suggest that there is no important general perturbation of the Na-K pump in hypertension per se.
Assuntos
Hiperinsulinismo/metabolismo , Hipertensão/metabolismo , Músculos/metabolismo , Obesidade/metabolismo , Potássio/metabolismo , Sódio/metabolismo , Transporte Biológico Ativo , Glicemia/metabolismo , Teste de Tolerância a Glucose , Humanos , Insulina/sangue , Masculino , Pessoa de Meia-Idade , Equilíbrio Hidroeletrolítico/fisiologiaRESUMO
The aim of this study was to characterize the acute effect of euglycemic (glucose 5.2 +/- 0.6 mmol/l) hyperinsulinemia (mean 118 +/- 32 mU/l) on fibrinolytic variables, free fatty acids (FFA) and counterregulatory hormones. In addition, the effect of chronic treatment with metformin, an oral antidiabetic agent which enhances insulin action, and metoprolol CR, a relatively beta 1-selective adrenergic antagonist, was also evaluated. A randomized, double-blind, placebo-controlled, cross-over study including 18 non-obese men, aged 53 +/- 6 years, was performed. The investigations were performed after each treatment period of 6 weeks in both the postabsorptive state and during a euglycemic, hyperinsulinemic clamp. Compared to the postabsorptive state, plasminogen activator inhibitor (PAI-1) activity and antigen, tissue plasminogen activator (t-PA) antigen and FFA decreased (p < 0.001) after 120 min of euglycemic hyperinsulinemia. In addition, t-PA activity increased (p < 0.01) while blood levels of lipoprotein (a), catecholamines and cortisol remained unchanged. Growth hormone increased during the clamps and this was most pronounced after treatment with metoprolol CR. When the effect of treatment was compared, postabsorptive levels of C-peptide, FFA and t-PA antigen were lower after metformin than after the placebo period (p < 0.05). t-PA antigen also remained lower during the clamp after metformin treatment. No significant effects of metformin or metoprolol CR were seen on insulin-stimulated glucose uptake during the clamps or on postabsorptive levels of counterregulatory hormones, PAI-1 or Lp(a).(ABSTRACT TRUNCATED AT 250 WORDS)
Assuntos
Fibrinólise/efeitos dos fármacos , Técnica Clamp de Glucose , Hormônios/metabolismo , Insulina/sangue , Metformina/farmacologia , Metoprolol/farmacologia , Estudos Cross-Over , Método Duplo-Cego , Jejum/sangue , Ácidos Graxos não Esterificados/sangue , Humanos , Absorção Intestinal/fisiologia , Lipoproteína(a)/sangue , Lipoproteína(a)/efeitos dos fármacos , Masculino , Pessoa de Meia-IdadeRESUMO
The present study was performed to elucidate the acute effect of insulin on levels of tissue plasminogen activator (t-PA) and plasminogen activator inhibitor of endothelial cell type (PAI-1). Nine middle-aged, non-obese and non-smoking men were studied during a hyperinsulinemic, euglycemic glucose clamp for 2 h. Plasma insulin level during the clamp averaged 84 +/- 12 mU/l and euglycemia was maintained at 4.9 +/- 0.6 mmol/l. The t-PA activity gradually increased (75% mean increase after 2 h, p less than 0.001) and the PAI-1 activity decreased (49% mean decrease after 2 h, p less than 0.001) during the clamp. t-PA activity decreased and PAI-1 activity increased after the insulin infusion was ceased, but they were still 48% higher and 38% lower, respectively, after 60 min. PAI-1 and t-PA activities were not affected by saline infusion for 2 h. Thus, acute changes in the insulin levels lead to rapid alterations in the fibrinolytic system even when euglycemia is maintained. These effects may be induced by insulin itself or by the concomitant activation of the sympatho-adrenal system during the euglycemic clamp.
Assuntos
Insulina/farmacologia , Inativadores de Plasminogênio/sangue , Ativador de Plasminogênio Tecidual/efeitos dos fármacos , Glicemia/metabolismo , Humanos , Insulina/sangue , Masculino , Pessoa de Meia-Idade , Ativador de Plasminogênio Tecidual/sangueRESUMO
The syndrome of growth hormone deficiency (GHD) in adults is associated with premature atherosclerosis, increased cardiovascular mortality, abnormal lipoprotein patterns and abnormal body composition. We have previously shown that GH-deficient adults have increased concentrations of fibrinogen and plasminogen activator inhibitor (PAI-1) activity. The aim of the present investigation was to study coagulation and fibrinolysis in 17 patients with adult-onset GHD during two years of treatment with recombinant human GH (12 micrograms/kg body weight/day). The impact of the contemporary changes in metabolic variables and body composition on coagulation and fibrinolysis was studied. The patients received conventional thyroid, adrenal and gonadal hormone replacement therapy. PAI-1 activity, PAI-1 antigen and tissue plasminogen activator (t-PA) antigen levels decreased during the GH treatment period (p < 0.05). The decrease was more pronounced in patients with high pre-treatment levels of the different variables. alpha 2-antiplasmin decreased (p < 0.05), while plasminogen was unchanged during two years of GH treatment. Fibrinogen concentrations tended to decrease after two years of GH treatment (p = 0.06), while the coagulation factors VII and VIII were unchanged. von Willebrand factor demonstrated a transient decrease after 18 months of GH treatment. The coagulation inhibitor, protein C, decreased (p < 0.05), while antithrombin was unchanged. Fasting plasma insulin increased (p < 0.01), but blood glucose did not differ after two years of GH treatment. Serum high-density lipoprotein cholesterol, total cholesterol and triglycerides were unaltered. Body fat decreased during the initial GH treatment but was unaltered after two years, while lean body mass increased (p < 0.001) and the waist over hip circumference ratio tended to decrease (p = 0.06). In conclusion, PAI-1 activity, PAI-1 antigen and t-PA antigen decreased during long-term GH treatment. These changes may be a direct effect of GH itself or may be secondary to the favourable changes in body composition. It remains to be seen whether changes in these fibrinolytic variables during rhGH treatment reduces the cardiovascular risk in patients with GHD. The present results suggest that GH plays a role in the regulation of fibrinolysis.
Assuntos
Hormônio do Crescimento/deficiência , Inibidor 1 de Ativador de Plasminogênio/sangue , Ativador de Plasminogênio Tecidual/sangue , Adulto , Idoso , Feminino , Fibrinogênio/análise , Fibrinólise , Hormônio do Crescimento/uso terapêutico , Humanos , Masculino , Pessoa de Meia-Idade , Fatores de TempoRESUMO
Obese people with a high waist/hip ratio (W/H ratio) have an increased risk for cardiovascular disease. The present study was designed to separately analyze the importance of obesity and the regional fat distribution for the metabolic risk factors. Blood pressure, glucose tolerance, insulin, and plasma lipid levels were studied in lean and obese postmenopausal women with a high or low W/H ratio. The individuals within each group were carefully matched for age, lean body mass, and body fat. The risk factors associated with a high W/H ratio (elevated blood pressure, blood lipids, and glucose levels) were found in the obese but not in the lean women. Furthermore, lean women with a high W/H ratio tended to have a lower metabolic risk factor profile than obese women with a low W/H ratio. These findings document the importance of obesity in expressing the metabolic risk factors for cardiovascular disease associated with a high W/H ratio.
Assuntos
Abdome , Tecido Adiposo , Composição Corporal , Obesidade/metabolismo , Antropometria , Pressão Sanguínea , Doenças Cardiovasculares/etiologia , Colesterol/sangue , Ácidos Graxos não Esterificados/sangue , Feminino , Teste de Tolerância a Glucose , Humanos , Insulina/sangue , Pessoa de Meia-Idade , Músculos , Fatores de Risco , Triglicerídeos/sangueRESUMO
Recent epidemiologic studies have shown that abdominal obesity, characterized by a high waist to hip circumference ratio (WHR), is associated with increased cardiovascular morbidity and mortality. The present study examines components of the fibrinolytic system in obese and lean middle-aged women with a high and low WHR. Ten women in each group were carefully matched with respect to age, body weight, lean body mass, and body fat. Fibrinogen and endothelial type of plasminogen activator inhibitor -1 (PAI-1) were significantly elevated in the obese women with a high WHR compared with the obese women with a low WHR or with both groups of lean women. In addition, obese women with a high WHR exhibited a greater metabolic risk profile (elevated glucose, insulin, and triglyceride levels). When all subjects were pooled for the analyses, both fibrinogen and PAI-1 levels correlated positively with glucose and insulin levels. PAI-1 was also negatively related to degree of insulin sensitivity measured with the euglycemic clamp technique. In the obese groups, WHR but not body mass index (BMI), correlated with PAI-1 levels. No such correlations were seen in the lean groups. In conclusion, the data show that a high WHR in obese, but not lean middle-aged women, is associated with an impaired fibrinolytic activity. This perturbation becomes enhanced when it is associated with hyperinsulinemia and insulin resistance, which is a typical feature of abdominal obesity.
Assuntos
Fibrinólise , Obesidade/sangue , Inativadores de Plasminogênio/sangue , Doenças Cardiovasculares/etiologia , Humanos , Insulina/sangue , Masculino , Pessoa de Meia-Idade , Fatores de Risco , Triglicerídeos/sangueRESUMO
Patients with growth hormone deficiency (GHD) have traditionally been described as having increased insulin sensitivity with a tendency toward fasting hypoglycemia, at least in children. In other studies, impaired glucose tolerance has been found. To evaluate basal insulin sensitivity, a hyperinsulinemic, normoglycemic clamp was performed with an insulin rate of 40 mU/m2/min after an overnight fast. Fifteen patients (four women and 11 men aged 20 to 62 years) with GHD for at least 1 year were compared with 15 healthy controls matched for sex, age, and body mass index (BMI). Thirteen patients had complete pituitary deficiency and were being treated with conventional hormone replacement therapy. Two men had isolated GHD since childhood. Four men were being treated with bromocriptin. There were no significant differences between fasting blood glucose (4.4 +/- 0.1 v 4.7 +/- 0.2 [mean +/- SEM] mmol/L) or fasting plasma insulin (9.5 +/- 1.4 v 8.8 +/- 1.1 mU/L) in patients and controls, respectively. Fasting free fatty acid (FFA) levels were lower in patients (444 +/- 35 v 796 +/- 94 mumol/L, P < .01). Blood glucose levels during the clamp were similar (4.6 +/- 0.1 v 4.9 +/- 0.1 mmol/L), as were insulin levels (81 +/- 4 v 93 +/- 4 mU/L). A decrease in glucose infusion rate (GIR) was seen during the clamp in GHD subjects (3.9 +/- 0.5 v 9.9 +/- 0.7 mg/kg body weight/min) as compared with controls (P = .001). Even if corrections were made for body fat, there was a significant difference (GIR corrected per lean body mass, 5.8 +/- 0.8 v 13.9 +/- 0.9 mg/kg lean body mass/min, P < .001). The results suggest that adults with GHD are insulin-resistant. Despite this finding, normal fasting plasma insulin levels were seen.
Assuntos
Hormônio do Crescimento/deficiência , Resistência à Insulina , Adulto , Glicemia/metabolismo , Índice de Massa Corporal , Jejum , Ácidos Graxos não Esterificados/sangue , Feminino , Humanos , Insulina/sangue , Masculino , Pessoa de Meia-Idade , Triglicerídeos/sangueRESUMO
Hypertension is related to several conditions with abnormalities in carbohydrate and lipid metabolism, such as obesity and impaired glucose tolerance. However, perturbed metabolism is also seen in non-obese hypertensive individuals. In addition, hypertension is linked to impaired fibrinolysis and elevated levels of the plasminogen activator inhibitor of endothelial type (PAI-1). Insulin resistance and hyperinsulinaemia in essential hypertension may be an important cause of these metabolic and fibrinolytic abnormalities. Whether hyperinsulinaemia is the cause of hypertension is currently unknown. However, it is clear that the relationship between hypertension and insulin is complex, and further studies are required to clarify this association. Based on the evidence states, it is suggested that insulin resistance and hyperinsulinaemia play a role in hypertension. However, it is also clear that hyperinsulinaemia occurs in the absence of hypertension, which suggests that other factors, such as genetic susceptibility, may be important.
Assuntos
Hipertensão/metabolismo , Doença das Coronárias/etiologia , Fibrinólise/fisiologia , Humanos , Hipertensão/complicações , Resistência à Insulina/fisiologia , Lipídeos/sangue , Obesidade/complicações , Obesidade/metabolismo , Fatores de RiscoRESUMO
Body composition calculated from total body potassium and skeletal muscle potassium were studied in middle-aged obese men and women with normal and impaired glucose tolerance as well as Type II diabetes before and after advice on calorie reduction during twelve months. The subjects were compared with healthy lean men and women. Mean weight loss was 6.6 kg (P less than 0.05). Lean body mass and body fat decreased 2.0 kg (P less than 0.05) and 4.6 kg (P less than 0.05), respectively. Total body potassium decreased by a mean of 146 +/- 49 mmol (P less than 0.01). Obese men with Type II diabetes and impaired glucose tolerance had lower total body potassium and muscle potassium levels than obese healthy men. After dieting, the obese men and women increased their muscle potassium levels with a mean of 2.8 mmol/100 fat-free dry weight to 42.6 +/- 2.6 mmol/100 g fat-free dry weight (P less than 0.05), but they were still below the levels of the lean controls, 44.4 +/- 1.3 MMOL/100 g fat-free dry weight, (P less than 0.01). Increase in skeletal muscle potassium was correlated to decrease in body weight, r = 0.55 (P less than 0.01) and to decrease in fasting blood glucose, r = 0.42 (P less than 0.05).
Assuntos
Diabetes Mellitus/dietoterapia , Músculos/metabolismo , Obesidade , Potássio/metabolismo , Glicemia/análise , Diabetes Mellitus/metabolismo , Diabetes Mellitus Tipo 2/dietoterapia , Diabetes Mellitus Tipo 2/metabolismo , Dieta Redutora , Feminino , Teste de Tolerância a Glucose , Hemoglobinas Glicadas/análise , Humanos , Masculino , Pessoa de Meia-Idade , Redução de PesoRESUMO
The relationship between hypertension, glucose metabolism, fibrinogen and plasminogen activator inhibitor of endothelial cell type (PAI-1) was studied under conditions in which the influence of obesity and adipose tissue distribution (waist/hip ratio) were controlled. Twenty-two non-obese, middle-aged men with normal blood pressure (n = 11) and untreated mild hypertension (n = 11), respectively, participated in the study. Cholesterol, triglyceride and insulin levels were higher in hypertensive men than in the control group. Glucose disposal was studied as an indicator of insulin sensitivity using the euglycaemic clamp technique. The insulin effect tended to be less marked in men with hypertension. PAI-1 was higher in hypertensive men compared to the controls. A strong positive correlation was observed between PAI-1 and insulin levels as well as blood pressure. PAI-1 and fibrinogen levels correlated negatively with the rate of glucose disposal. Thus, even in these non-obese and mildly hypertensive individuals, an enhanced metabolic risk factor profile for cardiovascular disease was found. The metabolic aberrations were related to elevated fibrinogen and PAI-1 levels which, in turn, increase the risk of thrombus formation.
Assuntos
Doenças Cardiovasculares/etiologia , Fibrinogênio/análise , Hipertensão/sangue , Inativadores de Plasminogênio/sangue , Antropometria , Pressão Sanguínea , Composição Corporal , Glucose/metabolismo , Humanos , Hipertensão/complicações , Hipertensão/metabolismo , Insulina/sangue , Lipídeos/sangue , Masculino , Pessoa de Meia-Idade , Fatores de RiscoRESUMO
Insulin resistance and hyperinsulinaemia may play an important role in both the development of hypertension and its accompanying metabolic aberrations. In order to investigate this possibility, nine non-obese, non-diabetic, non-smoking, middle-aged men with untreated hypertension were treated with metformin 850 mg b.i.d. for 6 weeks as a pilot study and within-patient comparison. Metformin decreased total and LDL-cholesterol (P less than 0.01), triglyceride (P less than 0.01), fasting plasma insulin (P less than 0.01) and C-peptide levels (P less than 0.02). Glucose disposal, an indicator of insulin action measured by means of the euglycaemic clamp technique, increased (P less than 0.001). Tissue plasminogen activator (t-PA) activity increased (P less than 0.02), and t-PA antigen decreased (P less than 0.01), whereas plasminogen activator inhibitor (PAI-1) and fibrinogen were unaffected by metformin treatment. Body weight remained unchanged. Withdrawal of metformin was associated with the return of both blood pressure and metabolism towards the initial levels. In conclusion, metformin treatment increased insulin action, lowered blood pressure, improved the metabolic risk factor profile and tended to increase the fibrinolytic activity in these mildly hypertensive subjects. These results support the view that insulin resistance plays a role in hypertension, and may open up a new field for the alleviation of abnormalities associated with cardiovascular disease.
Assuntos
Hipertensão/tratamento farmacológico , Resistência à Insulina/fisiologia , Metformina/uso terapêutico , Glicemia/metabolismo , Peptídeo C/sangue , Colesterol/sangue , LDL-Colesterol/sangue , Fibrinogênio/metabolismo , Humanos , Hipertensão/sangue , Hipertensão/fisiopatologia , Insulina/sangue , Masculino , Pessoa de Meia-Idade , Projetos Piloto , Inativadores de Plasminogênio/metabolismo , Fatores de Risco , Ativador de Plasminogênio Tecidual/metabolismo , Triglicerídeos/sangueRESUMO
The relation between blood pressure and skeletal muscle magnesium and potassium, and the relation between these electrolytes and body mass index, blood lipids, blood glucose and plasma insulin concentrations were studied in 29 hypertensive and 21 normotensive men. In addition, a comparison was made between the normotensive men and 37 normotensive women regarding the concentrations of muscle potassium and magnesium. Mean skeletal muscle potassium concentration was lower and plasma insulin higher in hypertensive compared to normotensives. Systolic and diastolic blood pressures were inversely correlated to muscle potassium and positively correlated to insulin. Muscle magnesium was positively correlated to muscle potassium but not to blood pressure. Muscle magnesium was significantly higher in normotensive women, compared to normotensive men. Muscle potassium did not differ between the genders.
Assuntos
Hipertensão/metabolismo , Magnésio/metabolismo , Músculo Esquelético/metabolismo , Potássio/metabolismo , Caracteres Sexuais , Adulto , Glicemia/metabolismo , Pressão Sanguínea , Índice de Massa Corporal , Feminino , Humanos , Insulina/sangue , Lipídeos/sangue , Masculino , Pessoa de Meia-Idade , Potássio/sangueRESUMO
OBJECTIVE: To study the effect of metformin and metoprolol CR on insulin sensitivity, blood lipids, fibrinolytic activity and blood pressure. DESIGN: A double-blind, placebo controlled, triple cross-over study with randomization to either metformin, 850 mg b.i.d., or metoprolol CR 100 mg o.d., or placebo for a period of 18 weeks. The glucose uptake was measured with the euglycaemic clamp technique after every 6 weeks' treatment period. Blood pressure and blood samples were taken every 3rd week. SUBJECTS: Eighteen non-obese men (53 +/- 6 years of age). RESULTS: Metformin decreased C-peptide (P < 0.02), FFA (P < 0.003), total and low-density lipoprotein cholesterol, tissue plasminogen activator antigen and the urinary potassium excretion (P < 0.05 for all), but not blood pressure compared to placebo. Metoprolol CR reduced diastolic blood pressure and pulse rate; fasting free fatty acids and the urinary potassium increased (P < 0.05 for all). No effect of metformin or metoprolol CR was seen on the glucose disposal rate, blood glucose, plasma insulin, triglycerides, high-density lipoprotein cholesterol, lipoprotein(a), uric acid or plasminogen activator inhibitor 1 activity or antigen. The glucose uptake was not particularly decreased in these subjects. CONCLUSION: The study shows that metformin has some favourable effects on metabolism and that metoprolol CR is fairly neutral in this regard. The lack of effect of metformin on glucose disposal rate and blood pressure can be explained by the fact that the individuals studied were neither insulin resistant nor hypertensive. The data does not preclude an antihypertensive effect by treating a concomitant insulin resistance.
Assuntos
Peso Corporal/fisiologia , Hipertensão/tratamento farmacológico , Metformina/uso terapêutico , Metoprolol/uso terapêutico , Análise de Variância , Antropometria , Pressão Sanguínea/efeitos dos fármacos , Preparações de Ação Retardada , Método Duplo-Cego , Fibrinólise/efeitos dos fármacos , Técnica Clamp de Glucose , Humanos , Hipertensão/sangue , Hipertensão/fisiopatologia , Insulina/sangue , Lipídeos/sangue , Masculino , Pessoa de Meia-IdadeRESUMO
OBJECTIVES: To study the relationship between insulin sensitivity and sodium-lithium countertransport (Na(+)-Li+ CT) in mild, essential hypertension, and to investigate the effect of metformin and metoprolol, respectively. DESIGN: A double-blind, triple cross-over, placebo-controlled study over a total period of 18 weeks. SETTING. A hypertension out-patient clinic and research laboratory at Sahlgrenska University Hospital. SUBJECTS: Seventeen non-obese men with mild essential -hypertension and 17 weight-matched, healthy controls. INTERVENTIONS: Metformin 850 mg b.i.d., metoprolol CR 100 mg once daily and placebo were given during 18 weeks. Each treatment period was 6 weeks. A euglycaemic clamp was performed and erythrocyte Na(+)-Li+ CT measured after each 6-week treatment period. MAIN OUTCOME MEASURES: Insulin sensitivity, erythrocyte Na(+)-Li+ CT, their interrelation, and the effect of metformin and metoprolol CR on both variables, respectively. RESULTS: The hypertensive men tended to have an elevated Na(+)-Li+ CT compared with the control subjects (0.34 +/- 0.03 versus 0.26 +/- 0.02 mmol L-1 h-1, P < 0.1). Glucose disposal rate was similar, but plasma insulin levels higher (P < 0.05) among the hypertensives than the controls. Na(+)-Li+ CT exhibited a positive relationship to BMI (r = 0.53, P = 0.03) and a negative correlation to glucose disposal rate (r = -0.66, P = 0.008) in the hypertensive subjects. In multiple regression analysis, Na(+)-Li+ CT showed a significant correlation to glucose disposal rate only. In the control subjects, there was no relation between glucose metabolism and Na(+)-Li+ CT. Neither metformin nor metoprolol influenced Na(+)-Li+ CT, glucose disposal rate or plasma insulin. CONCLUSION: Erythrocyte Na(+)-Li+ CT seemed to be closely related to insulin-glucose metabolism in mild hypertension, but was not influenced by metformin or metoprolol.
Assuntos
Anti-Hipertensivos/uso terapêutico , Antiporters/metabolismo , Hipertensão/tratamento farmacológico , Hipertensão/metabolismo , Insulina/sangue , Lítio/metabolismo , Metformina/uso terapêutico , Metoprolol/uso terapêutico , Sódio/metabolismo , Glicemia/metabolismo , Pressão Sanguínea , Índice de Massa Corporal , Estudos Cross-Over , Método Duplo-Cego , Eritrócitos/metabolismo , Técnica Clamp de Glucose , Humanos , Masculino , Pessoa de Meia-IdadeRESUMO
One hundred and sixty consecutive patients less than 50 years of age (mean 38 years) referred for long term electrocardiographic recording were evaluated retrospectively. Significant cardiac arrhythmias were detected in 51 of 107 (48%) patients examined because of syncope or dizzy spells or both. Of 39 patients examined for cardiac complaints or presumed complex arrhythmias, 15 (38%) had significant arrhythmias. Of 14 patients examined because of otherwise unexplained strokes, nine had slow sinus rates. Of these, one patient had recently undertaken moderately intensive athletic activity and four had been undertaking vigorous athletic activities for several years. All of the 12 active athletes who were followed up on account of syncope or dizzy spells were free of symptoms after reducing their athletic activities. The cardiac rhythm returned to normal in four out of five who underwent repeat long term electrocardiographic recording. It is suggested that vigorous athletic activity in subjects of 30-50 years of age may transform the adaptative bradycardia of the athlete into a condition similar to the embolising sick sinus syndrome.
Assuntos
Arritmias Cardíacas/complicações , Transtornos Cerebrovasculares/etiologia , Esportes , Adulto , Arritmia Sinusal/complicações , Arritmias Cardíacas/terapia , Tontura/etiologia , Eletrocardiografia , Feminino , Frequência Cardíaca , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Risco , Síncope/etiologiaRESUMO
A 61-year-old woman with Addison's disease and malignant lymphoma for several years was admitted to hospital with a 2-month history of fatigue and a 7 kg weight loss. The erythrocyte sedimentation rate was 92 mm h-1 and a temporal biopsy was performed as a part of the clinical investigation. She suddenly suffered a paresis of the right arm, sudden blindness and her blood pressure fell to 100/60 mmHg. Hydrocortisone was given intravenously followed by betamethasone, and an Addison crisis as well as a giant cell arteritis (GCA) was suspected. Activity in the malignant lymphoma was also a possibility. The patient did not improve and died 8 d later. The temporal biopsy indicated GCA. The autopsy showed a pronounced intimal inflammatory reaction of the intracerebral arteries and an infarction in the left posterior hemisphere. A possible link between GCA and other autoimmune diseases is discussed.
Assuntos
Doença de Addison/complicações , Arterite de Células Gigantes/etiologia , Linfoma/complicações , Artérias Cerebrais/patologia , Diagnóstico Diferencial , Feminino , Arterite de Células Gigantes/diagnóstico , Humanos , Pessoa de Meia-IdadeRESUMO
The effect of body weight on total body potassium, skeletal muscle electrolytes and fat content was studied in seven lean and seven obese middle-aged men and seven lean and eight obese middle-aged women. Total body potassium and total body fat increased with body weight (p less than 0.01 and less than 0.05 for men, and p less than 0.05 and p less than 0.001 for women, respectively). So did muscle fat in men (p less than 0.01), while muscle tissue potassium was decreased in both obese men (p less than 0.001) and obese women (p less than 0.05). The skeletal muscle Na/K-ratio tended to be higher in obese men (p less than 0.1) but was not related to body weight in women. Skeletal muscle magnesium was higher (p less than 0.01) in obese men than in lean men. No differences between lean and obese women were found. Obese men had higher diastolic blood pressure (p less than 0.05) than lean men, while there was no difference between obese and lean women. Compared with lean subjects, obese subjects thus had lower relative skeletal muscle mass and men, especially, had more fat and less potassium in the skeletal muscle.